Published in J Natl Cancer Inst on September 18, 2002
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature (2008) 5.98
The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer (2010) 4.06
Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol (2010) 3.54
Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res (2008) 3.05
Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol (2009) 2.94
Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J Pathol (2013) 2.35
Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res (2009) 2.04
Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res (2006) 1.80
Methylation not a frequent "second hit" in tumors with germline BRCA mutations. Fam Cancer (2009) 1.78
BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis. Fam Cancer (2006) 1.65
Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. Mol Oncol (2009) 1.61
Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance. J Clin Oncol (2008) 1.56
MYC in breast tumor progression. Expert Rev Anticancer Ther (2008) 1.49
Minireview: epigenetic changes in ovarian cancer. Endocrinology (2009) 1.49
Microenvironment and pathogenesis of epithelial ovarian cancer. Horm Cancer (2010) 1.30
Characterizing DNA methylation alterations from The Cancer Genome Atlas. J Clin Invest (2014) 1.27
Epigenetic therapies for chemoresensitization of epithelial ovarian cancer. Gynecol Oncol (2009) 1.26
Targeting DNA damage response in cancer therapy. Cancer Sci (2014) 1.16
CpG methylation of the FHIT, FANCF, cyclin-D2, BRCA2 and RUNX3 genes in Granulosa cell tumors (GCTs) of ovarian origin. Mol Cancer (2004) 1.14
Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer. PLoS One (2008) 1.14
Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. Mol Cancer (2009) 1.12
Induction of ovarian leiomyosarcomas in mice by conditional inactivation of Brca1 and p53. PLoS One (2009) 1.09
Epigenetic changes of DNA repair genes in cancer. J Mol Cell Biol (2011) 1.08
Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations. Neoplasia (2008) 1.08
PARP inhibitor treatment in ovarian and breast cancer. Curr Probl Cancer (2011) 1.08
BRCAness: finding the Achilles heel in ovarian cancer. Oncologist (2012) 1.05
The ups and downs of DNA repair biomarkers for PARP inhibitor therapies. Am J Cancer Res (2010) 0.95
Hereditary ovarian cancer and two-compartment tumor metabolism: epithelial loss of BRCA1 induces hydrogen peroxide production, driving oxidative stress and NFκB activation in the tumor stroma. Cell Cycle (2012) 0.95
Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer. Curr Opin Oncol (2012) 0.94
Ovarian surface epithelium: family history and early events in ovarian cancer. Reprod Biol Endocrinol (2003) 0.92
Epigenomics and ovarian carcinoma. Biomark Med (2010) 0.91
BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing. Oncotarget (2016) 0.90
Assays for hypermethylation of the BRCA1 gene promoter in tumor cells to predict sensitivity to PARP-inhibitor therapy. Methods Mol Biol (2011) 0.89
Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer. Pharmacogenomics (2012) 0.89
Mammary cancer susceptibility: human genes and rodent models. Mamm Genome (2007) 0.88
Ovarian cancer: in search of better marker systems based on DNA repair defects. Int J Mol Sci (2013) 0.87
DNA methylation profiles in ovarian cancer: implication in diagnosis and therapy (Review). Mol Med Rep (2014) 0.84
Translational application of epigenetic alterations: ovarian cancer as a model. FEBS Lett (2011) 0.83
Differentially methylated loci distinguish ovarian carcinoma histological types: evaluation of a DNA methylation assay in FFPE tissue. Biomed Res Int (2013) 0.81
Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy. J Cell Mol Med (2016) 0.81
Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing. J Gynecol Oncol (2017) 0.79
BRCA-associated ovarian cancer: from molecular genetics to risk management. Biomed Res Int (2014) 0.77
Detection of somatic BRCA1/2 mutations in ovarian cancer - next-generation sequencing analysis of 100 cases. Cancer Med (2016) 0.76
Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis. Fam Cancer (2016) 0.76
Clinicopathological values of NBS1 and DNA damage response genes in epithelial ovarian cancers. Exp Mol Med (2015) 0.75
Tumors that mimic asbestos-related mesothelioma: time to consider a genetics-based tumor registry? Front Genet (2014) 0.75
Molecular cytogenetics as a clinical test for prognostic and predictive biomarkers in newly diagnosed ovarian cancer. J Ovarian Res (2013) 0.75
Prevalence and clinical significance of BRCA1/2 germline and somatic mutations in Taiwanese patients with ovarian cancer. Oncotarget (2016) 0.75
Morphological and molecular basis of ovarian serous carcinoma. J Biomed Res (2010) 0.75
Poly ADP-ribose polymerase inhibitors: science and current clinical development. Curr Opin Oncol (2010) 0.75
Conditional knockout of brca1/2 and p53 in mouse ovarian surface epithelium: do they play a role in ovarian carcinogenesis? J Vet Sci (2010) 0.75
Characterization of BRCA1 and BRCA2 variants found in a Norwegian breast or ovarian cancer cohort. Fam Cancer (2017) 0.75
Molecular genetics complexity impeding research progress in breast and ovarian cancers. Mol Clin Oncol (2017) 0.75
Sequencing and analyses of all known human rhinovirus genomes reveal structure and evolution. Science (2009) 3.94
Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma. Cancer (2003) 2.48
Molecular modeling, organ culture and reverse genetics for a newly identified human rhinovirus C. Nat Med (2011) 1.96
Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics. Int J Cancer (2005) 1.84
Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin Cancer Res (2002) 1.57
Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination. Clin Cancer Res (2006) 1.51
Vascular endothelial growth factor and social support in patients with ovarian carcinoma. Cancer (2002) 1.45
p53 null mutations are associated with a telomerase negative phenotype in ovarian carcinoma. Cancer Biol Ther (2002) 1.41
Frequency of BRCA1 dysfunction in ovarian cancer. J Natl Cancer Inst (2002) 1.31
Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol (2002) 1.31
Quality of life and mood in women with gynecologic cancer: a one year prospective study. Cancer (2002) 1.28
Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer. Obstet Gynecol (2002) 1.17
Frequent attenuation of the WWOX tumor suppressor in osteosarcoma is associated with increased tumorigenicity and aberrant RUNX2 expression. Cancer Res (2010) 1.16
Analysis of the complete genome sequences of human rhinovirus. J Allergy Clin Immunol (2010) 1.06
Failure of BRCA1 dysfunction to alter ovarian cancer survival. Clin Cancer Res (2002) 0.97
5-millimeter trocar-site bowel herniation following laparoscopic surgery. JSLS (2013) 0.96
Osteoblastomatosis of bone. A benign, multifocal osteoblastic lesion, distinct from osteoid osteoma and osteoblastoma, radiologically simulating a vascular tumor. Skeletal Radiol (2006) 0.93
The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer. Clin Cancer Res (2005) 0.93
p21 expression predicts outcome in p53-null ovarian carcinoma. Clin Cancer Res (2003) 0.90
Neoadjuvant chemotherapy in vulvar cancer: avoiding primary exenteration. Gynecol Oncol (2005) 0.89
The impact of p53 protein core domain structural alteration on ovarian cancer survival. Clin Cancer Res (2003) 0.83
Ovarian cancer p53 mutation is associated with tumor microvessel density. Gynecol Oncol (2002) 0.83
Prolonged oral etoposide in recurrent or advanced non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol (2003) 0.82
Gene-based SNP mapping of a psychotic bipolar affective disorder linkage region on 22q12.3: association with HMG2L1 and TOM1. Am J Med Genet B Neuropsychiatr Genet (2008) 0.82
The influence of microvessel density on ovarian carcinogenesis. Gynecol Oncol (2003) 0.81
Late recurrence of juvenile granulosa cell tumor of the ovary. Am J Obstet Gynecol (2004) 0.81
Serum CA 125 is an independent prognostic factor in cervical adenocarcinoma. Am J Obstet Gynecol (2003) 0.79
Ovarian cancer risk assessment: a tool for preoperative assessment. Eur J Obstet Gynecol Reprod Biol (2011) 0.77
Should we be using cimetidine to premedicate patients receiving docetaxel or paclitaxel? Gynecol Oncol (2004) 0.77
Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial. Clin Cancer Res (2004) 0.76
Electrosurgical Settings and Vaginal Cuff Complications. JSLS (2015) 0.75
Primary carcinoma of the fallopian tube and epithelial ovarian carcinoma: a case-control analysis. J Reprod Med (2008) 0.75
Patients having prophylactic surgery for family history or known genetic mutations: why save the uterus? Gynecol Oncol (2007) 0.75
Increasing somatostatin analogues until effective. Gynecol Oncol (2005) 0.75
Assessment of False-negative Ascites Cytology in Epithelial Ovarian Carcinoma: A Study of 313 Patients. Am J Clin Oncol (2017) 0.75